Literature DB >> 9973196

The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts.

A B Buermeyer1, C Wilson-Van Patten, S M Baker, R M Liskay.   

Abstract

The DNA mismatch repair gene hMLH1 is reported to function in mutation avoidance, cell cycle checkpoint control, the cytotoxicity of various DNA-damaging agents, and transcription-coupled nucleotide excision repair. Formal proof of the involvement of hMLH1 in these processes requires single gene complementation. We have stably expressed hMLH1 from a transfected cDNA in Mlh1-deficient mouse embryonic fibroblasts. Expression of hMLH1 restored normal levels of mPMS2 protein, reduced spontaneous base substitution and microsatellite mutations, increased sensitivity to the toxic effects of 6-thioguanine (6-TG), and restored 6-TG-induced cell cycle arrest. Our studies confirm that hMLH1 has an essential role in the maintenance of genomic stability and the potentiation of 6-TG cytotoxicity and provide a system for detailed structure/function analysis of the hMLH1 protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973196

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Measurement of DNA mismatch repair activity in live cells.

Authors:  Xiufen Lei; Yong Zhu; Alan Tomkinson; LuZhe Sun
Journal:  Nucleic Acids Res       Date:  2004-07-12       Impact factor: 16.971

2.  Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Authors:  Svasti Haricharan; Nindo Punturi; Purba Singh; Kimberly R Holloway; Meenakshi Anurag; Jacob Schmelz; Cheryl Schmidt; Jonathan T Lei; Vera Suman; Kelly Hunt; John A Olson; Jeremy Hoog; Shunqiang Li; Shixia Huang; Dean P Edwards; Shyam M Kavuri; Matthew N Bainbridge; Cynthia X Ma; Matthew J Ellis
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

3.  Inactivation of DNA mismatch repair by increased expression of yeast MLH1.

Authors:  P V Shcherbakova; M C Hall; M S Lewis; S E Bennett; K J Martin; P R Bushel; C A Afshari; T A Kunkel
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

4.  The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair.

Authors:  Preeti Rajesh; Alexandra V Litvinchuk; Douglas L Pittman; Michael D Wyatt
Journal:  Mol Cancer Res       Date:  2011-01-04       Impact factor: 5.852

5.  The E705K mutation in hPMS2 exerts recessive, not dominant, effects on mismatch repair.

Authors:  Suzanne M Deschênes; Guy Tomer; Megan Nguyen; Naz Erdeniz; Nicole C Juba; Natalia Sepúlveda; Jenna E Pisani; R Michael Liskay
Journal:  Cancer Lett       Date:  2006-10-09       Impact factor: 8.679

6.  MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells.

Authors:  Zhiwei Zhong; Zhuo Dong; Lihua Yang; Xiaoqiang Chen; Zhaohui Gong
Journal:  Tumour Biol       Date:  2013-03-29

7.  Embryonic lethality after combined inactivation of Fancd2 and Mlh1 in mice.

Authors:  Henri J van de Vrugt; Laura Eaton; Amy Hanlon Newell; Mushen Al-Dhalimy; R Michael Liskay; Susan B Olson; Markus Grompe
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

8.  Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1.

Authors:  Petr Cejka; Lovorka Stojic; Nina Mojas; Anna Marie Russell; Karl Heinimann; Elda Cannavó; Massimiliano di Pietro; Giancarlo Marra; Josef Jiricny
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

9.  MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea.

Authors:  J R McDaid; J Loughery; P Dunne; J C Boyer; C S Downes; R A Farber; C P Walsh
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

10.  MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.

Authors:  X Ding; A B Mohd; Z Huang; T Baba; M Q Bernardini; H K Lyerly; A Berchuck; S K Murphy; A B Buermeyer; G R Devi
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.